Access to Approved CGTs |

<!DOCTYPE html> <html xmlns="http://www.w3.org/1999/xhtml"> <head>  <script type="text/javascript">(function (w, d, s, l, i) { w[l] = w[l] || []; w[l].push({ 'gtm.start': new Date().getTime(), event: 'gtm.js' }); var f = d.getElementsByTagName(s)[0], j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src = 'https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f); })(window, document, 'script', 'dataLayer', 'GTM-NFW5DS9');</script>   <script type="text/javascript"> //------------------------------------------------------- var z_account = "2632C1D8-6432-4D3A-93D6-08AAECC53F86"; var z_collector = "asgct.informz.net"; var z_cookieDomain = ".asgct.org"; //------------------------------------------------------- (function (e, o, n, r, t, a, s) { e[t] || (e.GlobalSnowplowNamespace = e.GlobalSnowplowNamespace || [], e.GlobalSnowplowNamespace.push(t), e[t] = function () { (e[t].q = e[t].q || []).push(arguments) }, e[t].q = e[t].q || [], a = o.createElement(n), s = o.getElementsByTagName(n)[0], a.async = 1, a.src = r, s.parentNode.insertBefore(a, s)) }(window, document, "script", "https://cdn.informz.net/web_trk/sp.js", "informz_trk")), informz_trk("newTracker", "infz", z_collector + "/web_trk/collector/", { appId: z_account, cookieDomain: z_cookieDomain }), informz_trk("setUserIdFromLocation", "_zs"), informz_trk("enableActivityTracking", 30, 15); informz_trk("trackPageView", null); </script>  <meta charset="utf-8" /> <meta http-equiv="X-UA-Compatible" content="IE=edge" /> <meta name="viewport" content="width=device-width,user-scalable=no,maximum-scale=1.0,initial-scale=1.0" /> <link href="/BlueKey/pe_assets/build/styles.css" rel="stylesheet" /> <script type="text/javascript" defer="defer" src="https://extend.vimeocdn.com/ga/127349852.js"></script> <meta name="twitter:card" content="summary_large_image" /> <meta name="twitter:site" content="https://twitter.com/ASGCTherapy" <meta name="twitter:creator" content="@ASGCTherapy" <meta name="twitter:title" content="Access to Approved CGTs" <meta name="twitter:image" content="~/attachment.aspx" <meta charset="UTF-8" /> <link href="/App_Themes/Default/Images/favicon.ico" type="image/x-icon" rel="shortcut icon" /> <link href="/App_Themes/Default/Images/favicon.ico" type="image/x-icon" rel="icon" /> <title> Access to Approved CGTs | </title></head> <body class="LTR IE IE7 ENUS ContentBody">  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-NFW5DS9" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>  <form method="post" action="/quick-takes/access-to-approved-cell-and-gene-therapies" id="aspnetForm"> <div class="aspNetHidden"> <input type="hidden" name="__CMSCsrfToken" id="__CMSCsrfToken" value="KzeQSRJyI9SnOdRkt2kYpphbl1Bvbew2B6uQi6ljjCCowRR4K2bxPJjcHkLu48vl2PAfZ687JPRCuM/YW2sxgqvkAGY=" /> <input type="hidden" name="__EVENTTARGET" id="__EVENTTARGET" value="" /> <input type="hidden" name="__EVENTARGUMENT" id="__EVENTARGUMENT" value="" /> <input type="hidden" name="__VIEWSTATE" id="__VIEWSTATE" value="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" /> </div> <script type="text/javascript"> //<![CDATA[ var theForm = document.forms['aspnetForm']; if (!theForm) { theForm = document.aspnetForm; } function __doPostBack(eventTarget, eventArgument) { if (!theForm.onsubmit || (theForm.onsubmit() != false)) { theForm.__EVENTTARGET.value = eventTarget; theForm.__EVENTARGUMENT.value = eventArgument; theForm.submit(); } } //]]> </script> <script src="/WebResource.axd?d=UZQNzmZXG1IdUaHxtavOjRvGEvOmz1kvw97PqEaxzBy7Ys-tUotw-RqgdbsvC3g_7cXjehqAdA_N6kbuK73WBAVGdxo1&t=638562384440000000" type="text/javascript"></script> <input type="hidden" name="lng" id="lng" value="en-US" /> <script type="text/javascript"> //<![CDATA[ function PM_Postback(param) { if (window.top.HideScreenLockWarningAndSync) { window.top.HideScreenLockWarningAndSync(1080); } if(window.CMSContentManager) { CMSContentManager.allowSubmit = true; }; __doPostBack('ctl00$CMSPortalManager1$am',param); } function PM_Callback(param, callback, ctx) { if (window.top.HideScreenLockWarningAndSync) { window.top.HideScreenLockWarningAndSync(1080); }if (window.CMSContentManager) { CMSContentManager.storeContentChangedStatus(); };WebForm_DoCallback('ctl00$CMSPortalManager1$am',param,callback,ctx,null,true); } //]]> </script> <script src="/ScriptResource.axd?d=WTJtoz6EJe-loUBJ9stbRxqzgpVp8oo0KdZGkhGfcu6Lr7kb5LeNfx21FKi8mxEL1oDZOLAxiAqERpClgBx-A6lZ0DJ1qKcDZB1NuIbRd8o9S7aG0&t=7c776dc1" type="text/javascript"></script> <script src="/ScriptResource.axd?d=y6KGkkRaceYF_mkApXCXMQ_rMQVX59BlJ-ut-lQDHw88bR5bbS86epdVNwimj01duE6_OophLX4sBTOgb8_5dNLaY2Mx5DHMJj7Rbr4kPMV1-AOS5VF5-QEC8oG-_-aHoWoyqA2&t=7c776dc1" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ var CMS = CMS || {}; CMS.Application = { "isDialog": false, "isDebuggingEnabled": false, "applicationUrl": "/", "isRTL": "false", "imagesUrl": "/CMSPages/GetResource.ashx?image=%5bImages.zip%5d%2f" }; //]]> </script> <div class="aspNetHidden"> <input type="hidden" name="__VIEWSTATEGENERATOR" id="__VIEWSTATEGENERATOR" value="AD1448C3" /> <input type="hidden" name="__EVENTVALIDATION" id="__EVENTVALIDATION" value="/wEdAAPCJAFwray69EZchGehx8lcDMN6QAizBz4KoPbUd79oAZD1NQdfl/cWuar5Vh7dGPQJDbZrX9CcV/MDv+cF7I132fiuUA==" /> </div> <script type="text/javascript"> //<![CDATA[ Sys.WebForms.PageRequestManager._initialize('ctl00$manScript', 'aspnetForm', ['tctl00$ctxM',''], [], [], 90, 'ctl00'); //]]> </script> <div id="ctl00_ctxM"> </div> <header class="c-header"> <a href="#content" class="show-on-focus">Skip to main content</a> <div class="c-header-utilities"> <div class="container"> <div class="columns is-vcentered"> <div class="column"> <a href="https://asgct.org" class="is-external">ASGCT.org</a> </div> <div class="column is-half"> <a href="/"> <div class="c-header-images"> <div class="c-header-image"> <img src="/PatientEducation/media/PatientEducation/ASGCT_Web_Horz_Navy.png?ext=.png" alt="" /> </div> <div class="c-header-image"> <img src="/PatientEducation/media/PatientEducation/temp-pe-logo.png?ext=.png" alt="Patient Education Logo" /> </div> </div> </a> </div>  <div class="column"> <div class="c-header-search"> <div class="c-header-search-wrap"> <input name="keyword" type="text" id="searchtext" placeholder="Search" aria-required="false" /> <label for="searchtext" class="is-sr-only">Keyword search</label> <button type="button" data-encode="searchtext" data-path="/search-results" data-query="searchtext"> <span class="is-sr-only">Search</span> <span class="c-search-icon"></span> </button> </div> </div> </div> </div> </div> </div> <div class="c-header-utilities-mobile"> <div class="c-header-images"> <div class="c-header-image"> <a href="https://asgct.org" class="is-external"><img src="/PatientEducation/media/PatientEducation/ASGCT_Web_Horz_Navy.png?ext=.png" alt="" /></a> </div> <div class="c-header-image"> <a href="/"><img src="/PatientEducation/media/PatientEducation/temp-pe-logo.png?ext=.png" alt="Patient Education Logo" /></a> </div> </div> <button class="c-nav-toggle" type="button" aria-controls="c-nav-main" aria-expanded="false" data-togglevisibility="data-togglevisibility"> <p class="is-sr-only">Open Navigation</p> <p class="is-sr-only" aria-hidden="true">Close Navigation</p> <span class="c-nav-toggle-menu"></span> </button> </div> <div id="ctl00_plcMain_bkSiteHeader_headerBanner"> <div class="header-alert"> <div class="container"> <p id="ctl00_plcMain_bkSiteHeader_pBanner"><b><a href="https://patienteducation.asgct.org/newsletter/subscribe-to-the-patient-press">Subscribe today to ASGCT's patient-centered newsletter, The Patient Press!</a></b></p> </div> </div> </div> <nav class="c-nav-main" id="c-nav-main" aria-hidden="true"> <div class="container"> <div class="c-header-search is-hidden-desktop"> <div class="c-header-search-wrap"> <input name="" type="text" id="global-search" placeholder="Search" aria-required="false" /> <label for="global-search" class="is-sr-only">Keyword search</label> <button type="button" data-encode="global-search" data-path="/search-results" data-query="searchtext"> <span class="is-sr-only">Search</span> <span class="c-search-icon"></span> </button> </div> </div> <ul> <li> <a href="/gene-therapy-101">Gene & Cell Therapy 101</a> <button type="button"><span class="is-sr-only">toggle subnavigation</span></button> <ul> <li> <a href="/gene-therapy-101/gene-therapy-basics">Gene Therapy Basics</a> </li> <li> <a href="/gene-therapy-101/cell-therapy-basics">Cell Therapy Basics</a> </li> <li> <a href="/gene-therapy-101/gene-therapy-approaches">Gene Therapy Approaches</a> </li> <li> <a href="/gene-therapy-101/gene-editing">Gene Editing</a> </li> <li> <a href="/gene-therapy-101/clinical-trials">Clinical Trials</a> </li> <li> <a href="/gene-therapy-101/vectors-101">Vectors 101</a> </li> <li> <a href="/gene-therapy-101/glossary">Glossary</a> </li> <li> <a href="/gene-therapy-101/covid19-vaccines">COVID-19</a> </li> </ul> <div class="navDropToggle"></div> </li> <li> <a href="/disease-treatments">Condition Treatments</a> <button type="button"><span class="is-sr-only">toggle subnavigation</span></button> <ul> <li> <a href="/disease-treatments/fda-approved-cell-gene-therapy-products">FDA-Approved Cell & Gene Therapy Products</a> </li> <li> <a href="/disease-treatments/batten">Batten Disease</a> </li> <li> <a href="/disease-treatments/blood-disorders">Beta Thalassemia & Other Blood Disorders</a> </li> <li> <a href="/disease-treatments/leukodystrophy">CALD and MLD</a> </li> <li> <a href="/disease-treatments/car-t-basics">CAR-T Basics</a> </li> <li> <a href="/disease-treatments/fabry">Fabry Disease</a> </li> <li> <a href="/disease-treatments/gaucher-disease">Gaucher Disease</a> </li> <li> <a href="/disease-treatments/gm1-gangliosidosis">GM1 Gangliosidosis</a> </li> <li> <a href="/disease-treatments/gm2-tay-sachs-sandhoff">Tay-Sachs and Sandhoff Disease</a> </li> <li> <a href="/disease-treatments/hemophilia">Hemophilia</a> </li> <li> <a href="/disease-treatments/huntingtons-disease">Huntington's Disease</a> </li> <li> <a href="/disease-treatments/inherited-retinal-diseases">Inherited Retinal Diseases</a> </li> <li> <a href="/disease-treatments/mps">Mucopolysaccharidoses (MPS)</a> </li> <li> <a href="/disease-treatments/muscular-dystrophy">Muscular Dystrophy</a> </li> <li> <a href="/disease-treatments/pompe-disease">Pompe Disease</a> </li> <li> <a href="/disease-treatments/parkinsons-disease">Parkinson's Disease</a> </li> <li> <a href="/disease-treatments/sickle-cell-disease">Sickle Cell Disease</a> </li> <li> <a href="/disease-treatments/sma">Spinal Muscular Atrophy</a> </li> <li> <a href="/disease-treatments/wilson-disease">Wilson Disease</a> </li> <li> <a href="/disease-treatments/xlmtm">X-Linked Myotubular Myopathy</a> </li> </ul> <div class="navDropToggle"></div> </li> <li> <a href="/patient-journey">Patient Journey</a> <button type="button"><span class="is-sr-only">toggle subnavigation</span></button> <ul> <li> <a href="/patient-journey/identifying-a-genetic-disease">Identifying a Genetic Disease</a> </li> <li> <a href="/patient-journey/next-steps-with-a-diagnosis">Next Steps With a Diagnosis</a> </li> <li> <a href="/patient-journey/patient-focused-policy-positions">Patient-Focused Policy Positions</a> </li> <li> <a href="/patient-journey/stimulating-research">Stimulating Research</a> </li> <li> <a href="/patient-journey/considering-a-clinical-trial">Considering a Clinical Trial</a> </li> <li> <a href="/patient-journey/ethical-issues-germline-gene-editing">Ethical Issues: Germline Gene Editing</a> </li> <li> <a href="/patient-journey/ethical-issues-illegitimate-clinical-trials">Ethical Issues: Unproven Stem Cell Products</a> </li> <li> <a href="/patient-journey/gene-therapy-centers">Gene Therapy Centers</a> </li> <li> <a href="/patient-journey/clinical-trials-finder">Clinical Trials Finder</a> </li> <li> <a href="/patient-journey/on-demand">On Demand Webinars</a> </li> </ul> <div class="navDropToggle"></div> </li> <li> <a href="/newsletter">Newsletter</a> <button type="button"><span class="is-sr-only">toggle subnavigation</span></button> <ul> <li> <a href="/newsletter/subscribe-to-the-patient-press">Subscribe to The Patient Press</a> </li> </ul> <div class="navDropToggle"></div> </li> <li> <a href="/quick-takes">Quick Takes</a> <button type="button"><span class="is-sr-only">toggle subnavigation</span></button> <ul> <li> <a href="/quick-takes/focused-ultrasound-in-cell-and-gene-therapies">Focused Ultrasound in CGTs</a> </li> <li> <a href="/quick-takes/access-to-approved-cell-and-gene-therapies">Access to Approved CGTs</a> </li> <li> <a href="/quick-takes/informed-consent">Informed Consent</a> </li> <li> <a href="/quick-takes/state-of-the-field-cgt-highlights-and-approvals-20">State of the Field: CGT Highlights and Approvals of 2023</a> </li> <li> <a href="/quick-takes/genetic-testing-and-clinical-trial-eligibility">Genetic Testing and Clinical Trial Eligibility</a> </li> </ul> <div class="navDropToggle"></div> </li> <li> <a href="/events">Events</a> <button type="button"><span class="is-sr-only">toggle subnavigation</span></button> <ul> <li> <a href="/events/empowering-patients-2025-a-cell-and-gene-therapies">Empowering Patients 2025: A Cell and Gene Therapies Summit</a> </li> <li> <a href="/events/annual-meeting-patient-advocate-offerings">Annual Meeting-Patient Advocate Offerings</a> </li> </ul> <div class="navDropToggle"></div> </li> <li> <a href="/about-asgct">About</a> <button type="button"><span class="is-sr-only">toggle subnavigation</span></button> <ul> <li> <a href="/about-asgct/overview">Overview</a> </li> <li> <a href="/about-asgct/about-asgct">About ASGCT</a> </li> <li> <a href="/about-asgct/news">ASGCT News</a> </li> <li> <a href="/about-asgct/privacy-policy">Privacy Policy</a> </li> </ul> <div class="navDropToggle"></div> </li> <li> <a href="/support">Support</a> </li> </ul> <a href="asgct.org" class="px-1 is-external is-hidden-desktop">ASGCT.org</a> </div> </nav> </header> <main class="c-main" id="content"> <section class="c-breadcrumbs"> <div class="container"> <span><a href="/">Home</a> > </span> <a href="/quick-takes" title="Quick Takes" class="CMSBreadCrumbsLink">Quick Takes</a> > <span class="CMSBreadCrumbsCurrentItem">Access to Approved CGTs</span> </div> </section> <section class="section"> <div class="container"> <div class="columns"> <div class="column is-8"> <h1 class="is-like-h2">Access to Approved Cell and Gene Therapies</h1> </div> </div> <div class="columns"> <div class="column is-8"> <div class="c-leader"> <div class="c-leader-content"><p>Patients accessing cell and gene therapies (CGTs) can face barriers in development, eligibility, coverage, referrals, and logistics. ASGCT experts discuss approved products, eligibility criteria, CAR-T lessons, provider knowledge, and how CGTs excite families compared to current sickle cell care.</p></div> </div> <div class="content mb-6"> <p>A person considering a gene or cell therapy treatment may experience barriers to accessing the treatment. Our experts will explore the various meanings of the term “access.”  This includes the development of therapies, eligibility to receive an FDA-approved treatment, coverage, provider referral, and being able to navigate the logistics of treatment within a clinic.  Each expert touches on aspects that shape the field and impact an individual’s access to gene and cell treatments.</p> <p>Listen to Quick Takes from experts in the community on the following questions (Time: 25 min):</p> <ul> <li>What are the mechanisms behind some current developments in CGTs, including approved products?</li> <li>How do certain eligibility criteria impact the ability of patient communities to access CGTs?</li> <li>What are some lessons learned from CAR-T approvals that might be relevant to newly approved products?</li> <li>What knowledge do providers have about these new treatments and how does this relate to access?</li> <li>What aspects of CGTs excite families more than standard care options when considering potential treatments (for SCD)?</li> </ul> <div style="padding:56.25% 0 0 0;position:relative;"><iframe allowfullscreen="" frameborder="0" src="https://vimeo.com/showcase/11176500/embed" style="position:absolute;top:0;left:0;width:100%;height:100%;"></iframe></div> <h2>Tell Us What You Think of Community Quick Takes!</h2> <p><a class="c-button-primary" href="https://asgct.qualtrics.com/jfe/form/SV_9TDluvmKsYacHJk" target="_blank">Evaluate this Program</a></p> <h2>Key Takeaways</h2> <p>There are many moving pieces that affect patient access to gene and cell therapies, and the speakers explored a few of these issues:</p> <ul> <li><a href="https://patienteducation.asgct.org/clinical-trials/understanding-a-clinical-trial-listing">Eligibility criteria</a>, including age range, status of disease progression, and past treatments, significantly influence who can receive approved gene and cell therapies. These criteria often fall under one of two main categories: delivery or scientific issues (i.e., gene size for vector and neutralizing antibodies) and the healthcare system (how they are prescribed and insurance coverage).</li> <li>Not all methods for delivering genetic material are viable for every disease or disorder. Many vectors, such as AAV (adeno-associated virus), have size limitations on the genetic material they can carry. This restricts the ability to address certain diseases using standard CGT approaches.</li> <li>The healthcare system is often unprepared to distribute new therapies effectively. Once a condition has an approved therapy, it does not mean all individuals with that condition will be eligible. There is a label that indicates who the treatment is approved for use in, which may exclude a segment of the population with the condition. Without wider efficacy data (to show the treatment works well in many people), insurance companies may deny coverage for the treatment.  Considering the often-small patient populations, alternative study designs – including decentralized studies, use of RWE (Real World Evidence), and patient experience data – are crucial in advancing research and understanding of gene and cell therapies.</li> <li>In 2023, the gene, cell, and RNA therapies pipeline grew by 6%. As a result, there are 3,951 such therapies in development, ranging from preclinical through pre-registration (filing for regulatory approval). The gene and cell therapy pipeline offers a unique opportunity to address many of these diseases for which there are currently no viable treatment options. To keep pace with the robust development pipeline, providers will require additional opportunities to learn about new and emerging treatment options, so they become more comfortable referring patients to receive CGTs if eligible. Advocacy at the legislative level is also important, with patients and families sharing how life-changing these treatments can be.</li> <li>Communities eligible for CGT treatments are excited about potential quality-of-life improvements. These treatments can alleviate the constant fear of health crises, allowing individuals to work and be active without the worry of frequent hospital visits (i.e. for those with sickle cell disease). Patients should be encouraged to discuss the viability, accessibility, and availability of new treatments with their healthcare providers.</li> </ul> <p>By understanding and addressing some of these areas, ASGCT members hope to better navigate the complexities of gene and cell therapies and improve access for those in need.</p> <h2>Conditions with Approved Products</h2> <p>Check out some of the current conditions with approved CGT treatments on the ASGCT Patient Education site:</p> <ul> <li><a href="https://patienteducation.asgct.org/disease-treatments/blood-disorders">Beta Thalassemia</a></li> <li><a href="https://patienteducation.asgct.org/disease-treatments/car-t-basics">Blood Cancers</a></li> <li><a href="https://patienteducation.asgct.org/disease-treatments/leukodystrophy">Cerebral Adrenoleukodystrophy (CALD)</a></li> <li><a href="https://patienteducation.asgct.org/disease-treatments/hemophilia">Hemophilia</a></li> <li><a href="https://patienteducation.asgct.org/disease-treatments/inherited-retinal-diseases">Inherited Retinal Diseases</a></li> <li><a href="https://patienteducation.asgct.org/disease-treatments/muscular-dystrophy">Muscular Dystrophy</a></li> <li><a href="https://patienteducation.asgct.org/disease-treatments/sickle-cell-disease">Sickle Cell Disease</a></li> <li><a href="https://patienteducation.asgct.org/disease-treatments/sma">Spinal Muscular Atrophy</a></li> </ul> <h2>Call to Action</h2> <p>As more approved CGT products come to market, multiple stakeholders will be involved in the discussions and decisions surrounding patient access. If you want to learn more about gene and cell therapy and want to further connect with those working to change the way individuals access treatments for rare diseases, consider <a href="https://asgct.org/membership/become-a-member">becoming an ASGCT member</a> or <a href="https://www.asgct.org/asgct-events?view=grid&startdate=2024-06-03">attending an upcoming ASGCT event</a>. If interested in receiving monthly updates about legislative proposals and coverage issues, <a href="https://asgct.informz.net/asgct/pages/The_Advocate_sign_up">subscribe to The Advocate</a>.</p> <h2>Was this information helpful?</h2> <p>If so, please share! All ASGCT Patient Education resources are free to use by sharing on social media, embedding the video, or simply linking to this page! <em>Please credit the American Society of Gene and Cell Therapy, and tag us on <a href="https://www.linkedin.com/company/asgct" target="_blank">LinkedIn</a>, <a href="https://www.instagram.com/asgctherapy/" target="_blank">Instagram</a>, <a href="https://www.facebook.com/ASGCTherapy/" target="_blank">Facebook</a>, and <a href="https://x.com/ASGCTherapy" target="_blank">X (formerly known as Twitter)</a>.</em></p> <h2>Thank You to Our Sponsors</h2> <p>The following companies offer their generous support of ASGCT's Community Quick Takes:</p> <p><br /> <a href="https://www.kitepharma.com/" target="_blank"><img alt="NEW-KITE-COLOR-LOGO.png" src="/getattachment/Community-Quick-Takes/Informed-Consent/NEW-KITE-COLOR-LOGO.png.aspx?width=163&height=51" style="width: 163px; height: 51px; margin: 20px;" title="NEW-KITE-COLOR-LOGO.png" /></a><img alt="lexeo-logo-250x100.png" src="/getattachment/Community-Quick-Takes/access-to-approved-Cell-and-gene-therapies/lexeo-logo-250x100.png.aspx?width=162&height=65" style="width: 162px; height: 65px; margin: 20px;" title="lexeo-logo-250x100.png" /><br /> <br /> <a href="https://sparktx.com/" target="_blank"><img alt="Spark-Logo.png" src="/getattachment/Community-Quick-Takes/Informed-Consent/Spark-Logo.png.aspx?width=165&height=61" style="width: 165px; height: 61px; margin: 20px;" title="Spark-Logo.png" /></a><a href="https://www.ultragenyx.com/" target="_blank"><img alt="LOGO_ultragenyxPH-CMYK.jpg" src="/getattachment/Community-Quick-Takes/Informed-Consent/LOGO_ultragenyxPH-CMYK.jpg.aspx?width=163&height=62" style="width: 163px; height: 62px; margin: 20px;" title="LOGO_ultragenyxPH-CMYK.jpg" /></a></p> </div> </div> <div class="column is-4 pl-4"> <div class="c-nav-local-wrap"> <div class="asideBox"> <h3> Related Pages</h3> <hr class="is-secondary" /> <ul class="c-nav-local-list"> <li class="c-nav-local-item"><a class="c-nav-local-link" href="/quick-takes/focused-ultrasound-in-cell-and-gene-therapies">Focused Ultrasound in CGTs</a> </li> <li class="c-nav-local-item is-active"><a class="c-nav-local-link" href="/quick-takes/access-to-approved-cell-and-gene-therapies">Access to Approved CGTs</a> </li> <li class="c-nav-local-item"><a class="c-nav-local-link" href="/quick-takes/informed-consent">Informed Consent</a> </li> <li class="c-nav-local-item"><a class="c-nav-local-link" href="/quick-takes/state-of-the-field-cgt-highlights-and-approvals-20">State of the Field: CGT Highlights and Approvals of 2023</a> </li> <li class="c-nav-local-item"><a class="c-nav-local-link" href="/quick-takes/genetic-testing-and-clinical-trial-eligibility">Genetic Testing and Clinical Trial Eligibility</a> </li> </ul> </div> </div> </div> </div> </div> <div class="lastUpdatedTag"> <p>Last Updated: 11/22/2024</p> </div> </section> </main> <footer class="c-footer"> <div class="c-footer-primary"> <section class="section"> <div class="container"> <div class="columns"> <div class="column c-footer-section"> <p><img alt="" src="/PatientEducation/media/PatientEducation/logo_white.png" /></p> <p>20800 Swenson Dr., Suite 300<br /> Waukesha, WI 53186</p> </div> <div class="column is-two-fifths c-footer-section"> <ul class="c-utility-list"> <li><a href="#">Gene Therapy 101</a></li> <li><a href="#">Disease Treatments</a></li> <li><a href="#">Clinical Trials</a></li> <li><a href="/patient-journey">Patient Journey</a></li> <li><a href="/about-asgct">About</a></li> <li><a href="/support">Support</a></li> <li><a href="https://asgct.org/about/privacy-policy" target="_blank">Privacy Policy</a></li> </ul> </div> <div class="column c-footer-section"> <h3 class="mb-3">Connect with ASGCT</h3> <p class="mb-0"><span>Phone: 414</span>.278.1341</p> <p><a href="mailto:info@asgct.org">info@asgct.org</a></p> <p> <div class="c-social"> <ul class="c-social-list"> <li class="c-social-item"><a href="https://twitter.com/ASGCTherapy" target="_blank" class="c-social-link twitter"><span class="is-sr-only">Twitter</span></a></li> <li class="c-social-item"><a href="https://www.facebook.com/ASGCTherapy" target="_blank" class="c-social-link facebook"><span class="is-sr-only">Facebook</span></a></li> <li class="c-social-item"><a href="https://www.instagram.com/asgctherapy" target="_blank" class="c-social-link instagram"><span class="is-sr-only">Instagram</span></a></li> <li class="c-social-item"><a href="https://www.linkedin.com/company/asgct" target="_blank" class="c-social-link linkedin"><span class="is-sr-only">LinkedIn</span></a></li> <li class="c-social-item"><a href="https://www.youtube.com/user/ASGCT" target="_blank" class="c-social-link youtube"><span class="is-sr-only">YouTube</span></a></li> </ul> </div> </p> </div> </div> </div> </section> </div> <div class="c-footer-secondary"> <section class="section py-4"> <div class="container"> <div class="columns"> <div class="column"> <p class="is-small">© 2024 All rights reserved. American Society of Gene & Cell Therapy.</p> <p class="is-tiny">Web design by <a href="https://www.reasononeinc.com/kentico" target="_blank">Reason One</a>. Powered by <a href="http://www.kentico.com" target="_blank">Kentico</a>.</p> </div> </div> </div> </section> </div> </footer> <div class="CookieConsent"> <span id="ctl00_cookieLawQ_lblText" class="ConsentText">This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.</span> <span class="ConsentButtons"> <input type="submit" name="ctl00$cookieLawQ$btnAllowSpecific" value="OPT OUT" id="ctl00_cookieLawQ_btnAllowSpecific" class="ConsentButton btn btn-default" /> <input type="submit" name="ctl00$cookieLawQ$btnAllowAll" value="ACCEPT" id="ctl00_cookieLawQ_btnAllowAll" class="ConsentButton btn btn-default" /> </span> </div> <script src="/BlueKey/pe_assets/build/main.js" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ var callBackFrameUrl='/WebResource.axd?d=nNME_ObE2oIDm535eYM9xWmIMy-HXBVdo54Ly6sA5tAYPS1aA-gFDzodlP9ijTBRgmjStONrH4-ISuRTp7slHiYkACw1&t=638562384440000000'; WebForm_InitCallback();//]]> </script> </form> </body> </html>

CINXE.COM

Access to Approved CGTs |